MGB-BP-3 / MGB Biopharma - LARVOL DELTA

Antibiotics with novel mode of action as new weapons to fight antimicrobial resistance. (PubMed, Eur J Med Chem) - "Today, the pipeline of potential new treatments with these characteristics includes promising compounds such as gepotidacin, zoliflodacin, ibezapolstat, MGB-BP-3, CRS-3123, afabicin and TXA-709, which are currently in clinical trials, and lefamulin, which has been recently approved by FDA and EMA. In this review, we report the chemical synthesis, mode of action, structure-activity relationships, in vitro and in vivo activities as well as clinical data of these eight small molecules listed above."

Journal • Review • Oncology

The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects. (PubMed, Biomedicines) - "Many possible drugs of the future for CDI, with diverse mechanisms of action, are in development in the form of microbiota-modulating agents (e.g., ADS024, CP101, RBX2660, RBX7455, SYN-004, SER-109, VE303, DAV132, MET-2, and BB128), small molecules (e.g., ridinilazole, ibezapolstat, CRS3123, DNV3837, MGB-BP-3, alanyl-L-glutamine, and TNP-2198), antibodies (e.g., IM-01 and LMN-201), and non-toxic strains of CD (e.g., NTCD-M3). The development of some therapeutic agents (e.g., DS-2969b, OPS-2071, cadazolid, misoprostol, ramoplanin, KB109, LFF571, and Ramizol) stopped due to failed clinical trials or unknown reasons...The current pipeline of anti-CDI medications appears promising. However, it will be fascinating to see how many of the cited are successful in gaining approval from drug regulators such as the US FDA and becoming medicines for CDI and r-CDI."

Journal • Review • Developmental Disorders • Infectious Disease

Insights into the Spectrum of Activity and Mechanism of Action of MGB-BP-3. (PubMed, ACS Infect Dis) - "These results highlight additional mechanisms of action of MGB-BP-3, including interference of the action of type II bacterial topoisomerases. While MGB-BP-3's lack of Gram-negative activity was confirmed, and an understanding of this presented, the recognition that MGB-BP-3 can target DNA of Gram-negative organisms will enable further iterations of design to achieve a Gram-negative active S-MGB."

Journal • Infectious Disease

Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI). (PubMed, J Exp Pharmacol) - "Updated CDI treatment guidelines suggest vancomycin and fidaxomicin as initial first-line therapies that have initial clinical cure rates of over 80%...Alternative treatments for rCDI include fecal microbiota transplant and a human monoclonal antibody, bezlotoxumab, that can be used in patients with high risk of rCDI. Various emerging potential therapies with narrow spectrum of activity and little systemic absorption that are in development include 1) Ibezapolstat (formerly ACX-362E), MGB-BP-3, and DS-2969b-targeting bacterial DNA replication, 2) CRS3213 (REP3123)-inhibiting toxin production and spore formation, 3) ramizol and ramoplanin-affecting bacterial cell wall, 4) LFF-571-blocking protein synthesis, 5) Alanyl-L-Glutamine (alanylglutamine)-inhibiting damage caused by C. difficile by protecting intestinal mucosa, and 6) DNV3837 (MCB3681)-prodrug consisting of an oxazolidinone-quinolone combination that converts to the active form DNV3681 that has activity in vitro..."

Journal • Review • Transplantation

[VIRTUAL] Phase IIa dose escalation treatment of Clostridioides difficile-associated diarrhea with MGB-BP-3, a novel first in class DNA minor grove binding antibiotic (ECCMID 2020) - "Background: MGB-BP-3 is a synthetic polyamide related to Distamycin A, which selectively binds to the minor grove of microbial DNA, is highly active against gram positive pathogens, has been found to be bactericidal vs C.difficile and associated with lower sporulation in-vitro as compared to vancomycin. MGB-BP-3 appears to be well tolerated and appears to merit further study as a CDAD treatment candidate."

P2a data

Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD (clinicaltrials.gov) - P2a; N=34; Completed; Sponsor: MGB Biopharma Limited; Recruiting ➔ Completed

Clinical • Trial completion